Now Reading: Maharashtra FDA cancels Cipla unit’s drug sale licences
-
01
Maharashtra FDA cancels Cipla unit’s drug sale licences
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding facility at Wadki in Pune, following inspections that found…
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding facility at Wadki in Pune, following inspections that found labelling violations on Reactin Plus tablets and other irregularities.
FDA officials said the packaging of Reactin Plus, a Schedule H prescription drug, carried the words 'analgesic and antipyretic', which is not permitted for such medicines as it could encourage self-medication. Stock worth Rs 11.2 lakh was seized and the company was directed to recall the product. A subsequent inspection of the C&F facility found discrepancies in stock records, inadequate storage, and lapses in handling expired medicines.
A Cipla spokesperson said the company has contested the order and clarified that no concerns about the safety, quality or efficacy of its products have been alleged. The matter is under judicial consideration.
Indian Opinion Analysis
Both outlets report the same regulatory action, but Hindustan Times frames it as a 'crackdown' and quotes FDA Commissioner Tukaram Mundhe's warning about strict compliance, reinforcing a pro-enforcement narrative. Times of India leads with the labelling violation and the company's contestation, giving more weight to Cipla's denial of any safety issue. The balanced reading: the FDA's action targets labelling and storage compliance, not drug quality, but the agency's public posture signals zero tolerance for Schedule H marketing lapses. The judicial challenge will test whether the penalty matched the violations.
Coverage: 2 sources, 1 pro-government, 1 neutral
Sources (2): timesofindia.indiatimes.com (neutral report), hindustantimes.com (pro government)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry.
